MedPath
HSA Approval

CLARIPEN GRANULES FOR ORAL SUSPENSION 125 mg/5 ml

SIN12429P

CLARIPEN GRANULES FOR ORAL SUSPENSION 125 mg/5 ml

CLARIPEN GRANULES FOR ORAL SUSPENSION 125 mg/5 ml

September 23, 2003

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence HolderTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

GRANULE, FOR SUSPENSION

ORAL

Medical Information

J01FA09

clarithromycin

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

ELPEN PHARMACEUTICAL CO INC

Sun Pharmaceutical Industries Limited (DP Intermediate)

Active Ingredients

CLARITHROMYCIN

125 mg/5 ml

Clarithromycin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CLARIPEN GRANULES FOR ORAL SUSPENSION 125 mg/5 ml - HSA Approval | MedPath